Epitome Therapeutics
PrivateLast Round
Grant
Jun 30, 2026
Total Funding Raised
$2.28M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Epitome Therapeutics operates in Healthcare & Life Sciences and is based in Vienna. Its latest recorded funding round was a Grant round in June 2026.
Epitome Therapeutics is a biotechnology company developing CADENCE, a programmable platform for precise and durable activation of endogenous genes to treat severe liver and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Epitome Therapeutics Comparables
Compare Epitome Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| General Control | 81% | |
| Tune Therapeutics | 79% | |
| nChroma Bio | 78% |
For institutional investors. Book with your work email.
Epitome Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Epitome Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Austria Wirtschaftsservice | Grant |
| xista science ventures | Grant |
| Caesar Ventures | Grant |
| FFG Austrian Research Promotion Agency | Grant |
| xista science ventures | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 30, 2026
$2.3M round led by Caesar Ventures and xista science ventures.
For institutional investors. Book with your work email.
Epitome Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Epitome Therapeutics's valuation, stock price, and market status.
Is Epitome Therapeutics a public or private company?
Epitome Therapeutics is a private company.
What is the current stock price of Epitome Therapeutics?
Epitome Therapeutics is a private company, so its shares have no public market price. Caplight tracks Epitome Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Epitome Therapeutics worth (valuation)?
Valuation information for Epitome Therapeutics is not publicly available.
Can I buy Epitome Therapeutics stock?
Epitome Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Epitome Therapeutics's last funding round?
Epitome Therapeutics's most recent funding round was Grant on June 30, 2026.
Who are the main investors in Epitome Therapeutics?
Key investors in Epitome Therapeutics include xista science ventures, Caesar Ventures, xista science ventures.
Will Epitome Therapeutics IPO soon?
No public IPO plans have been announced for Epitome Therapeutics.
How can I track Epitome Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Epitome Therapeutics's shares on secondary markets.